NTM Infection Management
Transforming Patient Care
-
Nontuberculous mycobacterial infections are now more commonly detected than tuberculosis in the United States
-
Data from across the globe notes an increase in case rates of infection over time
-
In a U.S. study from 2010, it was estimated that approximately 30 people per 100,000 population were infected
The economic and health-related quality of life burden of NTM-lung disease (NTM-LD) expenditures were found to be:
-
155% greater for patients with NTM-LD than control group 1 year after diagnosis
-
66% greater for patients with NTM-LD than control group 2 years after diagnosis14,15
personalized patient care
The Advantages of NTM Testing
The Eurofins Viracor PCR assay for Nontuberculous Mycobacterium allows for the detection & differentiation of MAC, MAbC & Mycobacterium spp. by RT-PCR, direct from clinical samples.
This assay is intended for use in the diagnosis of NTM infections, the genus mycobacterium, & sub / species identification of NTM infections alongside clinical data of the patient and other laboratory tests outcomes.
NTM BROCHURE:
Improved Detection and Diagnosis: Revolutionizing NTM Infection Management
14. Marras TK, et al. J Manag Care Spec Pharm. 2018;24(10):964-974.
15. Strollo SE, et al. Ann Am Thorac Soc. 2015;12(10):1458-1464.